Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation

Hua, Manqi; Xiong, Fei; Chong, Shan; Zhang, Zhuo; Liu, Qianxin; Hou, Jingyi; Zhang, Zhiqi; Gu, Zhichun; Cui, Xiangli; Cui, Yimin; Xu, Ling; Xiang, Qian

doi:10.1016/j.ctrv.2024.102827

Cancer Treatment Reviews

2024

DOI: 10.1016/j.ctrv.2024.102827

|View full text |Cite

Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation

Manqi Hua,

Fei Xiong,

Shan Chong

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Assessing real-world safety of plecanatide: a pharmacovigilance study based on the FDA adverse event reporting system

Zhang,

Yao,

Zhu

2024

Front. Pharmacol.

View full text Add to dashboard Cite

BackgroundPlecanatide is a selective gastrointestinal peptide used for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Given its widespread use, understanding the long-term safety of plecanatide in real-world settings is essential.MethodsData for this study were sourced from the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from the first quarter of 2017 to the second quarter of 2024. Disproportionality analysis methods were employed to quantify adverse event signals associated with plecanatide. Additionally, a Weibull distribution analysis was conducted to assess changes in adverse events over time. Sensitivity analyses were performed to enhance the robustness of the findings.ResultsA total of 861 cases associated with plecanatide were identified, including 2057 adverse event reports. Common positive adverse events included diarrhea, constipation, abdominal distension, dissatisfaction with treatment, rectal tenesmus, increased fecal volume, abnormal gastrointestinal sounds, and gastrointestinal motility disorders. The majority of adverse events related to plecanatide occurred within the first 7 days of treatment. Findings were consistent across sensitivity analyses.ConclusionThis study preliminarily explores the safety of plecanatide in real-world applications, revealing significant new adverse event signals. These findings provide important safety references for clinicians prescribing plecanatide for CIC and IBS-C.

show abstract

Assessing real-world safety of plecanatide: a pharmacovigilance study based on the FDA adverse event reporting system

Zhang,

Yao,

Zhu

2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation

Cited by 1 publication

References 46 publications

Assessing real-world safety of plecanatide: a pharmacovigilance study based on the FDA adverse event reporting system

Assessing real-world safety of plecanatide: a pharmacovigilance study based on the FDA adverse event reporting system

Contact Info

Product

Resources

About